Thu. Jun 19th, 2025

FDA Approves Alzheimer’s-fighting Drug Leqembi

Serious concentrated female microbiologist in sterile clothing and safety goggles sitting at table and dropping reagent in petri dish while doing research in laboratory

The Food and Drug Administration (FDA) has granted full approval to Leqembi, a drug developed by Japanese pharmaceutical company Eisai, for the treatment of mild dementia and other symptoms associated with early Alzheimer’s disease.

Leqembi is the first medication to demonstrate modest effectiveness in slowing cognitive decline in Alzheimer’s patients.

The FDA initially provided conditional approval to Leqembi in January based on preliminary findings that showed the drug’s ability to clear the brain plaque associated with Alzheimer’s disease.

The drug’s effectiveness was further validated in a larger study involving 1,800 patients, which demonstrated a five-month delay in memory and thinking decline among those receiving the treatment compared to those receiving a placebo.

FDA’s neurology drug director, Teresa Buracchio, stated that the confirmatory study provided evidence of the drug’s safety and efficacy in treating Alzheimer’s disease. However, the prescribing information for Leqembi will include a warning about potential side effects, including brain swelling and bleeding, although such risks are also associated with other plaque-targeting Alzheimer’s drugs.

The approval of Leqembi holds significant implications for Medicare and other insurance plans, as it now paves the way for coverage of the drug for Alzheimer’s patients. Medicare, the primary health coverage provider for the majority of Americans with Alzheimer’s, had previously withheld coverage pending the FDA’s full approval.

Concerns were raised about the financial burden of new plaque-targeting Alzheimer’s drugs like Leqembi on Medicare, given that the cost of a year’s supply of the drug amounts to around $26,500 for biweekly intravenous administrations.

Medicare administrator Chiquita Brooks-LaSure has confirmed that the program will immediately begin reimbursing for Leqembi following its FDA approval. However, additional requirements will be implemented, including the enrollment of Medicare recipients in a federal registry to monitor the drug’s real-world safety and effectiveness.

While Medicare coverage will now be available for Leqembi, the process of initiating patients on the drug may take time.

Doctors will need to verify the presence of the specific brain plaque targeted by Leqembi, and healthcare professionals will require training to administer the drug correctly. Ongoing monitoring through repeated brain scans will also be necessary to detect any potential adverse effects. These additional services and procedures may incur additional costs for hospitals and medical clinics.

Eisai estimates that approximately 100,000 Americans could be diagnosed with Alzheimer’s and eligible for treatment with Leqembi by 2026.

The drug, co-marketed with Biogen, has shown a slight delay in disease progression, as measured on cognitive scales. While some experts argue that the observed difference may be too subtle for patients and their families to notice, federal health advisers have deemed it meaningful and recommended full FDA approval of the drug during a public meeting in June.

New York Times bestselling author Dr. Con Colbert’s book Healthy Brain Zone shows how to reverse memory loss and reduce risks of dementia and Alzheimer’s.

Colbert says the key ingredient to fighting memory loss, dementia and Alzheimer’s isn’t in prescriptions or unnatural treatments, but in “a healthy, gut-friendly diet,” and understanding the brain-gut connection with the nutritional and dietary choices that support it.

More and more, science is proving that a healthy digestive system is the key to a healthy brain and body, Colbert writes.

James Lasher is Staff Writer for Charisma Media.

Leave a Reply

By submitting your comment, you agree to receive occasional emails from [email protected], and its authors, including insights, exclusive content, and special offers. You can unsubscribe at any time. (U.S. residents only.)

Your email address will not be published. Required fields are marked *

Related Podcasts

More News
You’re Growing Through It: A Word for the Weary Soul
You’re Growing Through It: A Word for the Weary Soul
Superstition or Spiritual Warfare? The Truth About Demon Trapping Bowls
Superstition or Spiritual Warfare? The Truth About Demon Trapping Bowls
Pastor Jack Hibbs: These Biblical Clues Reveal Your Spiritual Gift
Pastor Jack Hibbs: These Biblical Clues Reveal Your Spiritual Gift
Preparing for Spiritual Battle: How to Respond as Israel and Iran Head Toward War
Preparing for Spiritual Battle: How to Respond as Israel and Iran Head Toward War
Don’t Let Doubt Take You Out: Pastor Todd Has the Fix-All for Fear and Anxiety
Don’t Let Doubt Take You Out: Pastor Todd Has the Fix-All for Fear and Anxiety
Jonathan Cahn: 3 Times Prayer Changed the Course of America
Jonathan Cahn: 3 Times Prayer Changed the Course of America
Satan Targets the Weak: Why Your Prayer Life Determines Your Victory or Defeat
Satan Targets the Weak: Why Your Prayer Life Determines Your Victory or Defeat
Raised from the Dead: Real-Life Resurrection Testimony Goes Viral
Raised from the Dead: Real-Life Resurrection Testimony Goes Viral
Here’s What the Bible Really Says About the Mark of the Beast
Here’s What the Bible Really Says About the Mark of the Beast
When Prayer Turns to Witchcraft: 7 Ways Christians Might Be Praying Wrong
When Prayer Turns to Witchcraft: 7 Ways Christians Might Be Praying Wrong
previous arrow
next arrow
Shadow

Latest Videos
113K Subscribers
1.3K Videos
12.6M Views

Copy link